Mounjaro 7.5 mg Injection Pen

Description

Mounjaro 7.5 mg injection pen is a once-weekly injectable GLP-1 and GIP receptor agonist containing tirzepatide, clinically proven to reduce A1C levels and support healthy weight loss. It’s the third step in the Mounjaro dose progression, ideal for users who have successfully completed 2.5 mg and 5 mg phases.

Key Features:

• Dual incretin action (GLP-1 + GIP) for enhanced metabolic control

• Each pen delivers 7.5 mg tirzepatide per dose

• Once-weekly self-administered injection

• Improves insulin sensitivity and reduces appetite

• Backed by clinical research (FDA Approval Release)

Usage Instructions:

• Inject once per week, preferably on the same day each week

• Administer in the abdomen, thigh, or upper arm

• Rotate injection sites to avoid irritation

• Begin only after tolerating 5 mg dose for at least 4 weeks

• Always follow your doctor’s guidance

Mounjaro 7.5 mg Injection Pen Side Effects:

Possible side effects include nausea, fatigue, or digestive changes. These typically lessen over time. For safety information, see the FDA Medication Guide.

Storage Instructions:

• Refrigerate between 36°F and 46°F (2°C–8°C)

• Keep in original carton away from light

• Do not freeze; discard if frozen